2021
Plasmapheresis as an Early Treatment for Severe Hypertriglyceridemia, Acute Pancreatitis, and Diabetic Ketoacidosis
Kravetz AM, Sanghavi P, Bhargava V, Shi RZ, Nally LM. Plasmapheresis as an Early Treatment for Severe Hypertriglyceridemia, Acute Pancreatitis, and Diabetic Ketoacidosis. AACE Clinical Case Reports 2021, 7: 315-319. PMID: 34522772, PMCID: PMC8426612, DOI: 10.1016/j.aace.2021.03.009.Peer-Reviewed Original ResearchDiabetic ketoacidosisType 1 diabetesAcute pancreatitisSevere hypertriglyceridemiaNew-onset type 1 diabetesZinc transporter 8 autoantibodiesGlutamic acid decarboxylase 65Islet cell antigen 512Hospital day 5Courses of plasmapheresisType 2 diabetesCourse of treatmentPancreatitis symptomsLifestyle modificationCutaneous xanthomasHospital admissionSerious complicationsClinical statusInsulin deficiencyIntravenous fluidsInsulin infusionLipemia retinalisEarly treatmentEarly initiationEffective treatment
2019
Pharmacologic treatment options for type 1 diabetes: what’s new?
Nally LM, Sherr JL, Van Name MA, Patel AD, Tamborlane WV. Pharmacologic treatment options for type 1 diabetes: what’s new? Expert Review Of Clinical Pharmacology 2019, 12: 471-479. PMID: 30892094, PMCID: PMC6488361, DOI: 10.1080/17512433.2019.1597705.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAdjunctive therapyType 1 diabetesInsulin analoguesMimic physiologic insulin secretionGLP-1 receptor agonistsPhysiologic insulin secretionPharmacologic treatment optionsDPP-4 inhibitorsType 2 diabetesVariety of insulinBiosynthetic human insulinPotential adverse effectsSGLT1/2 inhibitorsBasal insulinPharmacologic treatmentTreatment optionsReceptor agonistInsulin secretionSGLT-2Abnormal physiologyProlonged durationTherapyDiabetesInsulinNovel drugs
2018
Case 6: KCNJ11 R201C – Neonatal Diabetes
Nally L, Wilson D. Case 6: KCNJ11 R201C – Neonatal Diabetes. 2018, 61-66. DOI: 10.2337/9781580406666.case6.Peer-Reviewed Original Research